Here's How Novavax's Vaccine Stacks Up Against Moderna's and Pfizer's
Novavax (NASDAQ: NVAX) shares climbed 2,700% last year as investors bet on the biotech company's investigational coronavirus vaccine. But the share price's story doesn't end there. Last week, the stock soared nearly 65% in just one trading session. What prompted such a jump? Novavax said its vaccine candidate was effective against the U.K. and South African strains of the virus in clinical trials. This was welcome news given one of the biggest worries these days -- that currently available vaccines won't hold up against these new strains. The company also reported phase 3 efficacy data concerning the older version of SARS-CoV-2.
You're probably asking yourself whether all of this offers Novavax an advantage over its more advanced rivals, Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). The U.S. Food and Drug Administration (FDA) offered their vaccines Emergency Use Authorization (EUA) late in 2020. Let's take a closer look at three key points to see how Novavax measures up.
Image source: Getty Images.
Source Fool.com
